# Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

> **NCT06504901** · — · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Interleukin-2
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Neupogen

## Key facts

- **NCT ID:** NCT06504901
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2025-07-10
- **Final completion:** 2027-07-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06504901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06504901, "Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06504901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*